Actively Recruiting

Phase 3
Age: 75Years +
All Genders
NCT04257487

Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study)

Led by Arianna Anticoagulazione Foundation · Updated on 2024-07-31

1455

Participants Needed

1

Research Sites

314 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The study aims at optimizing extended management of elderly patients (\> 75 years) with at least one of the known bleeding risk factor, who suffered from first episode of venous thromboembolism of the lower extremity (proximal deep vein thrombosis with or without pulmonary embolism) (VTE). Patients were randomized to receive three different treatment: Sulodexide 250 mg BIS in die; Sulodexide 500 BID in die or indistinguishable placebo to verify the efficacy and safety of extended treatment for 12 months with Sulodexide (Vessel®) in the secondary prevention of Deep Vein Thrombosis / Pulmonary Embolism (DVT/PE) recurrence.

CONDITIONS

Official Title

Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study)

Who Can Participate

Age: 75Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  1. Patients with a first event of proximal lower extremity DVT and / or PE, idiopathic or associated with weak or removed risk factors.

  2. Patients aged ≥75 years at the time of enrolment

  3. Patients with at least one of the known risk factors of bleeding (APPENDIX 1):

    1. Hypertension
    2. Renal failure
    3. Thrombocytopenia
    4. Diabetes
    5. Antiplatelet therapy (ASA maximum 140 mg/die)
    6. Frequent falls (>2 /years)
    7. Nonsteroidal anti-inflammatory drug
    8. Liver failure
    9. Previous Stroke
    10. Anemia
    11. Poor anticoagulant control
    12. Alcohol abuse

  4. Patients of both sexes.

  5. Patients who at the time of enrolment have already undergone a period of anticoagulant therapy (AT, with any medication) of at least 3 months and the therapy has not been suspended for more than 30 days.

  6. Patients with no other AT indications.

  7. Patients capable and able to provide informed consent

Not Eligible

You will not qualify if you...

  1. Patients aged <75 years at the time of the recruitment visit.

  2. "Provoked" index event, which occurred:

    • Within 3 months of surgery or major trauma,
    • Bed Rest > 4 days,
    • Cast / immobility within 3 months.

  3. Index event represented by severe PE, with life threatening risk or treated with thrombolytic therapy.

  4. Index event represented by isolated distal DVT or superficial venous thrombosis.

  5. Thrombotic event in sites other than the deep proximal veins of the lower limbs.

  6. Anticoagulant therapy for less than 3 months at the time of enrolment.

  7. Discontinuation of anticoagulant therapy for over thirty days at the time of enrolment

  8. Recurrent episodes of DVT ± PE

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Corrado Lodigiani

Rozzano, Italy, 20089

Actively Recruiting

Loading map...

Research Team

C

Cristina Legnani, BSc, PhD

CONTACT

E

Emilia Antonucci, CR

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here